X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1082) 1082
Publication (92) 92
Book Review (21) 21
Book Chapter (5) 5
Conference Proceeding (4) 4
Data Set (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (833) 833
topotecan (803) 803
oncology (662) 662
female (549) 549
male (415) 415
index medicus (357) 357
middle aged (329) 329
adult (325) 325
topotecan - administration & dosage (318) 318
aged (313) 313
cancer (303) 303
animals (295) 295
pharmacology & pharmacy (284) 284
chemotherapy (279) 279
pharmacokinetics (274) 274
topotecan - pharmacokinetics (265) 265
camptothecin - analogs & derivatives (257) 257
antineoplastic agents - pharmacokinetics (245) 245
neoplasms - drug therapy (200) 200
antineoplastic agents - administration & dosage (191) 191
camptothecin (191) 191
mice (190) 190
antineoplastic combined chemotherapy protocols - therapeutic use (187) 187
antineoplastic agents - therapeutic use (175) 175
phase-i (172) 172
camptothecin - pharmacokinetics (160) 160
topotecan - adverse effects (157) 157
drug administration schedule (154) 154
topotecan - therapeutic use (146) 146
dose-response relationship, drug (145) 145
treatment outcome (145) 145
irinotecan (135) 135
solid tumors (134) 134
antineoplastic agents - adverse effects (130) 130
infusions, intravenous (123) 123
cisplatin (120) 120
ovarian neoplasms - drug therapy (114) 114
camptothecin - administration & dosage (112) 112
topoisomerase i inhibitors (112) 112
topotecan - pharmacology (112) 112
antineoplastic agents - pharmacology (111) 111
lung neoplasms - drug therapy (110) 110
medicine & public health (110) 110
cell line, tumor (104) 104
child (104) 104
paclitaxel (103) 103
topoisomerase-i (102) 102
cell lung-cancer (100) 100
administration, oral (99) 99
phase-ii (96) 96
care and treatment (95) 95
camptothecin - therapeutic use (94) 94
antineoplastic combined chemotherapy protocols - adverse effects (93) 93
trial (92) 92
pharmacodynamics (89) 89
pharmacology/toxicology (89) 89
adolescent (87) 87
research (86) 86
tumors (85) 85
child, preschool (84) 84
toxicity (84) 84
area under curve (83) 83
drug resistance, neoplasm (83) 83
children (82) 82
antineoplastic agents (81) 81
ovarian cancer (81) 81
camptothecin - pharmacology (80) 80
camptothecin - adverse effects (76) 76
antimitotic agents (75) 75
xenografts (74) 74
antineoplastic combined chemotherapy protocols - administration & dosage (73) 73
maximum tolerated dose (72) 72
atp binding cassette transporter, sub-family g, member 2 (71) 71
dna topoisomerase-i (70) 70
neoplasm recurrence, local - drug therapy (70) 70
carboplatin (69) 69
carcinoma (69) 69
drug therapy (69) 69
combination (68) 68
antitumor-activity (67) 67
aged, 80 and over (65) 65
analysis (65) 65
multidrug-resistance (65) 65
hematology (64) 64
neoplasms - metabolism (64) 64
etoposide (63) 63
antineoplastic combined chemotherapy protocols - pharmacokinetics (61) 61
article (59) 59
bioavailability (59) 59
drugs (58) 58
topoisomerase-i inhibitor (58) 58
cpt-11 (57) 57
doxorubicin (57) 57
oral topotecan (57) 57
p-glycoprotein (57) 57
expression (55) 55
rats (54) 54
therapy (54) 54
cisplatin - administration & dosage (53) 53
clinical trials (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1072) 1072
Japanese (7) 7
French (6) 6
German (4) 4
Italian (4) 4
Chinese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2016, Volume 13, Issue 11, pp. 659 - 673
Metronomic chemotherapy describes the close, regular administration of chemotherapy drugs at less-toxic doses over prolonged periods of time. In 2015, the... 
IN-VITRO | ANTIANGIOGENIC ACTIVITY | ONCOLOGY | RANDOMIZED PHASE-II | BREAST-CANCER PATIENTS | ANTITUMOR INNATE IMMUNITY | ORAL TOPOTECAN | CYCLOPHOSPHAMIDE TREATMENT | ANTICANCER DRUGS | CLINICAL PHARMACOKINETICS | DOSE CHEMOTHERAPY | Angiogenesis Inhibitors - immunology | Pyrimidines - immunology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Breast Neoplasms - immunology | Alkylating Agents - immunology | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Colorectal Neoplasms - drug therapy | Tubulin Modulators - administration & dosage | Alkylating Agents - pharmacokinetics | Camptothecin - administration & dosage | Female | Camptothecin - immunology | Camptothecin - pharmacokinetics | Pyrimidines - administration & dosage | Tubulin Modulators - pharmacokinetics | Alkylating Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Breast Neoplasms - drug therapy | Forecasting | Randomized Controlled Trials as Topic | Immunity, Cellular - immunology | Colorectal Neoplasms - immunology | Tubulin Modulators - immunology | Pyrimidines - pharmacokinetics | Chemotherapy | Care and treatment | Patient outcomes | Forecasts and trends | Pharmacokinetics | Observations | Methods | Cancer | Index Medicus
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
Journal Article
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 01/2017, Volume 24, Issue 2, pp. 193 - 214
Journal Article
Molecular Pharmacology, ISSN 0026-895X, 01/2007, Volume 71, Issue 1, pp. 240 - 9
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2013, Volume 72, Issue 1, pp. 127 - 138
Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial... 
Medicine & Public Health | Drug distribution | Tumor microenvironment | Normal tissues | Oncology | Cancer Research | Topotecan | Pharmacology/Toxicology | Mitoxantrone | Doxorubicin | MOUSE PLASMA | SOLID TUMORS | TOPOISOMERASE-I | PENETRATION | CANCER | CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | BLOOD-VESSELS | ADRIAMYCIN | PHARMACOLOGY & PHARMACY | PHASE-I | Doxorubicin - blood | Neoplasms - metabolism | Topoisomerase I Inhibitors - metabolism | Liver - pathology | Kidney - blood supply | Kidney - pathology | Humans | Topotecan - metabolism | Antibiotics, Antineoplastic - blood | Coronary Vessels - metabolism | Neovascularization, Pathologic - pathology | Antineoplastic Agents - metabolism | Tissue Distribution | Kidney - metabolism | Liver - drug effects | Myocardium - metabolism | Female | Antineoplastic Agents - pharmacokinetics | Doxorubicin - metabolism | Topotecan - blood | Antibiotics, Antineoplastic - pharmacokinetics | Topoisomerase I Inhibitors - pharmacokinetics | Coronary Vessels - drug effects | Coronary Vessels - pathology | Kidney - drug effects | Mitoxantrone - metabolism | Mitoxantrone - blood | Liver - metabolism | Myocardium - pathology | Neoplasms - blood supply | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Neovascularization, Pathologic - drug therapy | Topotecan - pharmacokinetics | Antineoplastic Agents - blood | Cell Line, Tumor | Mice | Neovascularization, Pathologic - metabolism | Mitoxantrone - pharmacokinetics | Topoisomerase I Inhibitors - blood | Antibiotics, Antineoplastic - metabolism | Neoplasms - pathology | Anthracyclines | Care and treatment | Drug wholesalers | Analysis | Fluorescence | Tumors | Cancer | Index Medicus | Antitumor agents
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2012, Volume 30, Issue 4, pp. 1493 - 1500
Background The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered... 
Medicine & Public Health | Targeted agents | PARP inhibitors | Oncology | Topotecan | Olaparib | Maximum tolerated dose | Pharmacology/Toxicology | DNA repair | SENSITIVITY | INDUCTION | CANCER | MAMMARY-TUMORS | ONCOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Topotecan - adverse effects | Treatment Outcome | Piperazines - therapeutic use | Neoplasms - diagnostic imaging | Topotecan - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Maximum Tolerated Dose | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Aged | Phthalazines - adverse effects | Cohort Studies | Studies | Clinical trials | Inhibitor drugs | Drug therapy | Patients | Tumors | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2006, Volume 12, Issue 18, pp. 5481 - 5490
Journal Article